title: Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype.
abstract: We have compared the growth and tumor-directed cytotoxic efficacy of recombinant-interleukin-2-(rIL-2)-activated peripheral blood (PBL) and tumor-infiltrating lymphocytes (TIL) from patients with epithelial ovarian carcinoma. These studies demonstrated that TIL and PBL displayed similar levels of cytotoxicity and a broad range of target cell killing, as exemplified by their reactivity against autologous and allogeneic ovarian tumors as well as against tumor cell lines. No specificity of autologous tumor cell killing was manifested by TIL. Even though TIL of some patients showed higher proliferative activity (especially at the later times in rIL-2 culture) this was not a general phenomenon. In fact, in one case TIL did not proliferate at all, and in the other case the PBL proliferated more actively. While the cultures were composed primarily of CD3+ lymphocytes, the major cytotoxic cells displayed the CD56+ and CD16+ phenotype. Addition of OKT3 mAb to rIL-2 cultures resulted in an increased proliferative index, but showed only a minor effect on the cytotoxic potential of cultured lymphocytes. The therapeutic potential of rIL-2-activated TIL and PBL is discussed.
authors.affiliation: Department of General Surgery, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
authors.forename: E
authors.initials: E
authors.lastname: Lotzová
authors.forename: C A
authors.initials: CA
authors.lastname: Savary
authors.forename: R S
authors.initials: RS
authors.lastname: Freedman
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: M
authors.initials: M
authors.lastname: Morris
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D004848:Epithelium / Q000473:pathology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D011994:Recombinant Proteins
chemical_list: D015703:Antigens, CD; D007376:Interleukin-2; D011994:Recombinant Proteins